Morgan Roupret, MD, PhD, from the Pitié-Salpétrière Hospital, Paris, France, discusses what uro-oncologists should know about new drugs in 2017 at the European Association of Urology (EAU) conference 2017 in London, UK. Prof. Roupret highlights the importance of clinical implications, and explains why clinicians should be informed about what is most important in the management of the disease and treatment side effects.
What should uro-oncologist know about new drugs in 2017?
